Lymphoproliferative Disease
Reduced-intensity BEAM-alemtuzumab SCT effective
Published in Clinical Oncology Week, March 29th, 2004
In a recent study, hematologists in England evaluated the results of "reduced-intensity allogeneic stem-cell transplantation using BEAM-alemtuzumab conditioning (carmustine, etoposide, cytosine arabinoside, melphalan, and alemtuzumab 10 mg/d on days -5 to -1) in six United Kingdom transplant centers."
"Sixty-five patients with lymphoproliferative diseases underwent sibling (n=57) or matched unrelated donor (n=8) transplantation," explained R.D. Faulkner and coauthors at Nottingham City Hospital.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- Women's Health
Chemo improves survival after cryoreductive surgery for ovarian, peritoneal cancer - Tumor Classification
New system combines molecular biology and classic pathology - Stem-Cell Transplantation
Treosulfan-fludarabine conditioning regimen safe and effective - Surgery
Surgical training should be emphasized in gynecologic oncology fellowship - Stem-Cell Transplantation
RIC SCT feasible for patients with advanced solid tumors - Stem-Cell Research
Endothelial progenitor cells are detected in infantile hemangioma - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
